Business Context and Reporting Period
This Form 8-K Current Report was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on January 25, 2023. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California. The report details a specific financing event and the issuance of unregistered equity securities.
Key Financial Metrics and Obligations
- Debt Financing: AgeX borrowed the remaining $500,000 under a Secured Convertible Promissory Note with Juvenescence Limited.
- Total Principal: The company has now drawn the maximum principal amount of $13,160,000 under this line of credit.
- Repayment Date: The outstanding principal balance is due on February 14, 2024.
- Cost of Capital: In lieu of accrued interest, the company pays an Origination Fee equal to 4% of each draw amount, plus an additional 4% of the total funds drawn after the 12-month draw period.
- Equity Issuance: AgeX issued warrants to purchase 340,136 shares of common stock at an exercise price of $0.735 per share.
Material Changes
The primary material change reported is the final drawdown of the Secured Note facility, bringing the total outstanding principal to $13.16 million. This action triggers the issuance of additional warrants to the lender. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period, as this is a current report focused on a specific transaction rather than a periodic financial statement.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors.
- Events of Default: The Secured Note contains extensive default provisions, including failure to pay principal or fees, breach of covenants, cross-defaults on other indebtedness exceeding $100,000, insolvency, bankruptcy proceedings, loss of material assets, or material adverse changes in financial condition.
- Acceleration: Upon an Event of Default, the outstanding principal and other amounts may become immediately due and payable.
- Liquidity Contingency: The company's ability to service this debt is contingent on its financial condition and operational performance, as defined by the lender's discretion regarding material adverse changes.
Investor Verification Checklist
- Verify the total outstanding debt obligation of $13.16 million and the specific repayment schedule due February 14, 2024.
- Confirm the total cost of the loan, including the 4% per-draw origination fee and the additional 4% fee on total funds drawn.
- Review the dilution impact of the 340,136 warrants issued at $0.735 per share.
- Assess the company's current liquidity position against the immediate repayment risk if an Event of Default occurs.
- Check for any other indebtedness exceeding $100,000 that could trigger a cross-default under the Secured Note.